MNA-001 / Muna Therap - LARVOL DELTA

Phase 1 First-in-Human Single And Multiple Ascending Dose Study Of The Novel Small Molecule TREM2 Agonist MNA-001 In Healthy Subjects (AAIC 2026) - No abstract available

Clinical • First-in-human • P1 data

Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer’s Disease (PRNewswire) - "Phase 1 study initiated to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects of MNA-001 on biomarkers of TREM2 target engagement and activation, with topline data expected mid 2026."

P1 data • Trial status • Alzheimer's Disease